Compile Data Set for Download or QSAR
Report error Found 100 Enz. Inhib. hit(s) with all data for entry = 10562
TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550470(US11583538, Example 118 | US11306098, Example 36)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550447(US11583538, Example 105 | US11306098, Example 14B ...)
Affinity DataIC50: 1.00E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550449(US11583538, Example 16 | US11306098, Example 15)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550449(US11583538, Example 16 | US11306098, Example 15)
Affinity DataIC50: 1.00E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550450(US11583538, Example 4 | US11306098, Example 16)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550450(US11583538, Example 4 | US11306098, Example 16)
Affinity DataIC50: 1.00E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550451(US11583538, Example 17 | US11306098, Example 17)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550451(US11583538, Example 17 | US11306098, Example 17)
Affinity DataIC50: 1.00E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550452(US11583538, Example 18 | US11306098, Example 18)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550452(US11583538, Example 18 | US11306098, Example 18)
Affinity DataIC50: 1.00E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550453(US11583538, Example 19 | US11306098, Example 19)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550460(US11583538, Example 43 | US11306098, Example 26)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550465(US11583538, Example 48 | US11306098, Example 31)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550467(US11583538, Example 50 | US11306098, Example 33)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550468(US11583538, Example 51 | US11306098, Example 34)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550433(US11583538, Example 1 | US11306098, Example 1)
Affinity DataIC50: 1.00E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550470(US11583538, Example 118 | US11306098, Example 36)
Affinity DataIC50: 1.00E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550471(US11583538, Example 52 | US11306098, Example 37)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550472(US11306098, Example 38)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550472(US11306098, Example 38)
Affinity DataIC50: 1.00E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550473(US11583538, Example 62 | US11306098, Example 39)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550473(US11583538, Example 62 | US11306098, Example 39)
Affinity DataIC50: 1.00E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550474(US11306098, Example 40)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550477(US11306098, Example 44 | US11306098, Example 43)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550477(US11306098, Example 44 | US11306098, Example 43)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550479(US11306098, Example 45)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550479(US11306098, Example 45)
Affinity DataIC50: 1.00E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550480(US11306098, Example 46)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550482(US11583538, Example 121 | US11306098, Example 48)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550482(US11583538, Example 121 | US11306098, Example 48)
Affinity DataIC50: 1.00E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550433(US11583538, Example 1 | US11306098, Example 1)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550447(US11583538, Example 105 | US11306098, Example 14B ...)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550439(US11583538, Example 7 | US11306098, Example 6)
Affinity DataIC50: 1.00E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550439(US11583538, Example 7 | US11306098, Example 6)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550438(US11583538, Example 6 | US11306098, Example 5)
Affinity DataIC50: 1.00E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550438(US11583538, Example 6 | US11306098, Example 5)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550437(US11583538, Example 5 | US11306098, Example 4)
Affinity DataIC50: 1.00E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550437(US11583538, Example 5 | US11306098, Example 4)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550436(US11583538, Example 3 | US11306098, Example 3)
Affinity DataIC50: 1.00E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550444(US11583538, Example 12 | US11306098, Example 11)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550436(US11583538, Example 3 | US11306098, Example 3)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550434(US11583538, Example 2A | US11306098, Example 2B | ...)
Affinity DataIC50: 1.00E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550434(US11583538, Example 2A | US11306098, Example 2B | ...)
Affinity DataIC50: 1.00E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550442(US11583538, Example 10 | US11306098, Example 9)
Affinity DataIC50: 5.50E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550477(US11306098, Example 44 | US11306098, Example 43)
Affinity DataIC50: 5.50E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550465(US11583538, Example 48 | US11306098, Example 31)
Affinity DataIC50: 5.50E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550466(US11583538, Example 49 | US11306098, Example 32)
Affinity DataIC50: 5.50E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550467(US11583538, Example 50 | US11306098, Example 33)
Affinity DataIC50: 5.50E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Human)
Venenum Biodesign

US Patent
LigandPNGBDBM550441(US11583538, Example 9 | US11306098, Example 8)
Affinity DataIC50: 5.50E+3nMAssay Description:To evaluate the effect of compounds on TREX1 activity, test compounds were serially diluted (11-point, 3-fold) from 10 mM stock solutions and deliver...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

TargetThree-prime repair exonuclease 1(Mouse)
Venenum Biodesign

US Patent
LigandPNGBDBM550468(US11583538, Example 51 | US11306098, Example 34)
Affinity DataIC50: 5.50E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 100 total ) | Next | Last >>
Jump to: